ICMR Patna gets nod for kala-azar drug trial
Hindustan TimesThe Rajendra Memorial Research Institute of Medical Sciences, one of the centres of the Indian Council of Medical Research, has got the nod to begin the phase II clinical drug trial of a new kala-azar drug, code named LXE408, officials said on Sunday. Muzaffarpur and Patna are the two locations in India where the Drugs for Neglected Diseases initiative, a Geneva-based organisation, has chosen to conduct the phase II trials for new kala-azar drug. RMRIMS will join the Kala-Azar Medical Research Centre, a charitable trust in Bihar’s Muzaffarpur district, where the trial was initiated last August, said Dr Krishna Pandey, director of ICMR-RMRI centre at Agamkuan in Patna. Depending on the availability of patients, based on the inclusion and exclusion criteria fixed by the Drug Controller General of India, and their consent, we will begin the phase II trials shortly after finalisation of the randomisation list of patients,” said Dr Pandey, also the principal investigator of the trial.
History of this topic
ICMR signs MoAs to advance first-in-human clinical trials for four promising molecules
The Hindu
ICMR signs agreements to advance first-in-human Phase 1 clinical trials
New Indian Express
Trial on new Kala Azar drug to begin at ICMR’s Patna research centre
Hindustan Times
ICMR helping Serum Institute in conducting clinical trials for two vaccines
Live MintDiscover Related
)
